Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Leptin Signaling in Lean and Obese Humans (Leptin signali)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Department of Veterans Affairs Identifier:
First received: February 14, 2011
Last updated: August 11, 2014
Last verified: August 2014

February 14, 2011
August 11, 2014
April 2011
April 2016   (final data collection date for primary outcome measure)
Westerns / activation of signaling pathways (uo to two hours after treatment) [ Time Frame: 04/01/2016 ] [ Designated as safety issue: No ]
Westerns / activation of signaling pathways [ Time Frame: 04/01/2016 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01297426 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Leptin Signaling in Lean and Obese Humans
Leptin Signaling in Humans

Obesity does not respond to high circulating levels of the hormone leptin. This study is aiming at finding out why this happens and open new avenues for treatment of obesity.

Ex vivo and in vitro identification and study of leptin signaling pathways in commercially available cell lines serum/ plasma samples and discarded tissues from humans.

Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

diabetic or nondiabetic lean and obese subjects

Not Provided
Group 1
Lean and obese, diabetic and non diabetics
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
April 2016
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • men and women
  • ages 18 to 65
  • BMI ranges between 20 and 45 kg/m2

Exclusion Criteria:

  • subjects requiring special diets
  • history of illness other than obesity of diabetes
  • taking medications known to influence glucose metabolism
  • subjects with history of anaphylactic reaction or hypersensitivity to e. coli derived proteins or anesthetic agents
  • women who are breastfeeding, pregnant or wanting to become pregnant
  • subjects with bleeding dyscrasia or poor wound healing
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
United States
Department of Veterans Affairs
Department of Veterans Affairs
Not Provided
Principal Investigator: Christos Mantzoros, MD DSc VA Medical Center, Jamaica Plain Campus
Department of Veterans Affairs
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP